atx

ATX inhibitor 5 is a potent and orally active autotaxin (ATX) inhibitor (IC50: 15.3 nM) that reduces CCl4-induced hepatic fibrosis and exhibits anti-hepatic fibrosis effects.

ATX inhibitor 1 is a potent ATX inhibitor with IC50 values of 1.23 nM (FS-3) and 2.18 nM (bis-pNPP).

ATX-002 is a property-tunable lipid for RNA drug delivery.

ATX inhibitor 7 is an autotaxin inhibitor that demonstrates good oral exposure.

ATX-0114 is an ionizable cationic lipid [1].

Z-HA155 (CS-963) selectively and potently inhibits autotaxin with an IC50 of 5.7 nM.

Autotaxin-IN-3 is an inhibitor of Autotaxin (IC50 = 2.4 nM) which is responsible for the increase in lysophosphatidic acid in ascites and plasma.

(±)-Anatoxin A hydrochloride is the salt form of (±)-Anatoxin A.(±)-Anatoxin A is a potent neurotoxic naturally occurring alkaloid known as a rapid death factor (VFDF), a potent, direct, and selective agonist of the nAchR (nicotinic acetylcholine receptor), also known as the nicotinic receptor agonist.

CRT0273750 regulates plasma LPA levels and is suitable for in vivo studies. CRT0273750 is an autotaxin (ATX) inhibitor with IC50 of 0.014 μM.

BIO-32546 (S-isomer) is a highly potent regulator of autotaxin (ATX) with an IC50 value of 1 nM.

HA 155 (Autotaxin Inhibitor IV) is a boronic acid-based compound, inhibiting ATX with IC50 of 5.7 nM by selectively binding to its catalytic threonine.

HA130 is a selective ATX (autotaxin) inhibitor.

ONO-8430506 is an orally available, potent autotaxin (ATX)/ENPP2 inhibitor (IC90: 100 nM) that inhibits ATX activity in mouse plasma.

Cudetaxestat (BLD-0409) is a potent, orally active autotaxin inhibitor.

DHX9-IN-2 is an inhibitor targeting ATP-dependent RNA de-helicase A (DHX9) with anticancer and antitumor activity for cancer research.

mRNA-Encapsulating Lipid Excipient 1 (Compound 2), a thiocarbamate-based ionizable lipid, serves as an excipient in the formulation of mRNA-encapsulating lipid nanoparticles [1].

ATX inhibitor 25 (Compound 29) is an orally active Autotaxin inhibitor with an IC50 of 1.08 nM. It exhibits excellent in vitro metabolic stability, with a half-life (t1/2) of over 170 minutes. In a bleomycin-induced pulmonary fibrosis mouse model, ATX inhibitor 25 (administered orally) shows antifibrotic effects.

ATX-IN-1 (compound 35) is an ATX inhibitor with an IC50 of 0.7 nM, demonstrating anti-inflammatory properties. It effectively suppresses the TGF-β/Smad pathway and reduces collagen deposition, alleviating fibrosis in a Bleomycin-induced mouse model. This compound also exhibits good oral bioavailability (F=69.5%) and microsomal stability.

ATX inhibitor 26 is an Autotaxin (ATX) inhibitor with an IC50 of 57 nM in human plasma. It effectively inhibits cell migration and collagen gel contraction. Additionally, ATX inhibitor 26 demonstrates significant antifibrotic activity, reducing collagen deposition in a Bleomycin (BLM)-induced pulmonary fibrosis model.

ATX inhibitor 27 (Compound 31) is an ATX inhibitor. It demonstrates IC50 values of 13 nM against human autotaxin (hATX) and 23 nM against lysophosphatidylcholine (LPC). By inhibiting the ATX enzyme, ATX inhibitor 27 reduces LPA levels in the body. This compound is applicable in research related to ATX-LPA-associated conditions such as inflammation, neurodegenerative disorders, and cancer.

ATX inhibitor 24 is a potent ATX inhibitor with an IC50 of 7.51±0.72 nM, demonstrating antitumor activity.

ATX-IN-3 is an orally active autotaxin (ATX) inhibitor with an IC50 of 46 nM. It effectively ameliorates pulmonary fibrosis in mouse models by significantly reducing collagen deposition. ATX-IN-3 demonstrates excellent metabolic stability and drug-like properties, making it suitable for research on idiopathic pulmonary fibrosis (IFP).

ATX inhibitor 15 (compound 30) is an indole-based carbamate derivative with a strong inhibitory effect on autotaxin (ATX), demonstrated by an IC50 of 2.17 nM. It effectively inhibits ATX activity in vivo, suppresses the expression of pro-fibrotic genes, and exhibits protective effects in Bleomycin-induced lung fibrosis in mice [1].

ATX inhibitor 9 is a thickened heteroaryl derivative compound and a potent inhibitor of ATX. Among them Autotaxin (ATX), also known as ENPP2, is a secreted enzyme highly expressed mainly in lung cancer cells, bronchial epithelial cells and alveolar macrophages.ATX inhibitor 9 has research potential for cancer or fibrous degenerative diseases.